Design of an irreversible electroporation system for clinical use.

IGEA S.r.l., Via Parmenide, 10/A, I-41012 Carpi (MO) Italy.
Technology in cancer research & treatment (Impact Factor: 1.89). 09/2007; 6(4):313-20. DOI: 10.1177/153303460700600408
Source: PubMed

ABSTRACT Irreversible electroporation is an ablation modality in which microseconds, high-voltage electrical pulses are applied to induce cell necrosis in a target tissue. To perform irreversible electroporation it is necessary to use a medical device specifically designed for this use. The design of an irreversible electroporation system is a complex task in which the effective delivery of high energy pulses and the safety of the patient and operator are equally important. Pulses of up to 3000 V of amplitude and 50 A of current need to be generated to irreversibly electroporate a target volume of approximately 50 to 70 cm3 with as many as six separate electrodes; therefore, a traditional approach based on high voltage amplifiers becomes hard to implement. In this paper, we present the process that led to the first irreversible electroporator capable of such performances approved for clinical use. The main design choices and its architecture are outlined. Safety issues are also explained along with the solutions adopted.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Irreversible electroporation (IRE) is a promising new minimally invasive modality for the ablation of solid tumors. Unlike the current leading thermal ablation modalities, such as radiofrequency ablation (RFA) and cryoablation, IRE uses nonthermal electric energy to irreversibly destabilize cell membranes, resulting in focused cell death. Over the past 7 years, IRE has been emerging as a novel ablation tool by using the effect of an applied electric field to kill cancer cells, without damaging the surrounding extracellular matrix, vessels, nerves, and neighboring normal tissue. Although IRE has been investigated for a short period of time, its potential use for cancer and tissue ablation has been receiving growing attention leading to a considerable number of studies on its validity and safety, including recent in vivo animal and human studies.
    06/2014; DOI:10.1016/j.gii.2014.02.002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Electroporation is used to enhance drug diffusion and gene delivery into the cytosol. The combination of electroporation and cytotoxic drugs, electrochemotherapy (ECT), is used to treat metastatic tumor nodules located at the skin and subcutaneous tissue. The objective response rate following a single session of treatment exceeds 80%, with minimal toxicity for the patients. The efficacy of ECT in the bone and visceral metastasis is currently investigated, and Phase II studies have been completed. ECT has been used to treat skin primary tumors, except melanoma, and is under investigation for locally advanced pancreatic cancer. Early evidence suggests that treatment of tumor nodules with ECT recruits components of the immune system and eliciting a systemic immune response against cancer is a challenging clinical perspective. Considering the proven safety in several different clinical applications electroporation should be viewed as a clinical platform technology with wide perspectives for use in ECT, gene therapy and DNA vaccination.
    Future Oncology 04/2014; 10(5):877-90. DOI:10.2217/fon.13.235 · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pulsed high-electric fields are used to electroporate biological cells. Here we describe different applicators and generators used in electroporation applications, with emphasis on clinical and industrial electroporators and safety issues.


Available from
Jun 5, 2014